Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors

• Main Authors: Michael Menzel (Author), Martina Kirchner (Author), Klaus Kluck (Author), Markus Ball (Author), Susanne Beck (Author), Michael Allgäuer (Author), Christin Assmann (Author), Johannes Schnorbach (Author), Anna‐Lena Volckmar (Author), Timothy Kwang Yong Tay (Author), Hannah Goldschmid (Author), Daniel SW Tan (Author), Michael Thomas (Author), Daniel Kazdal (Author), Jan Budczies (Author), Albrecht Stenzinger (Author), Petros Christopoulos (Author)
• Format: Book
• Published: Wiley, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This study analyzed whether extended molecular profiling can predict the development of epidermal growth factor receptor (EGFR) gene T790M mutation, which is the most frequent resistance alteration in non‐small cell lung cancer (NSCLC) after treatment with the first‐/second‐generation (1G/2...